CatalYm’s monoclonal antibody visugromab bags $150M
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.| Labiotech.eu
Those are our privacy policies, showing you how we respect your privacy and your data, so we all live in a happy and non-spammy world :)| Labiotech.eu
Get the latest biotech news for Immunotherapy, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.| Labiotech.eu
